Navigation
Search
|
Weight-Loss Surgery Down 25% as Anti-Obesity Drug Use Soars
Thursday October 31, 2024. 03:00 PM , from Slashdot
Using a national sample of medical insurance claims data from more than 17 million privately insured adults, the researchers identified patients with a diagnosis of obesity without diabetes in 2022-2023. The study found a sharp increase in the share of patients who received glucagon-like peptide-1 receptor agonists, or GLP-1 RAs, during the study period, with GLP-1 RA use increasing 132.6% from the last six months of 2022 to the last six months of 2023 (from 1.89 to 4.41 patients per 1,000 patients). Meanwhile, there was a 25.6% decrease in use of bariatric metabolic surgery during the same period (from 0.22 to 0.16 patients per 1,000 patients). Among the sample of patients with obesity, 94.7% received neither form of treatment during the study period (while 5% received GLP-1 RAs and 0.3% received surgery). Compared to patients who were prescribed GLP-1 RAs, patients who underwent surgery tended to be more medically complex. Read more of this story at Slashdot.
https://science.slashdot.org/story/24/10/31/1230224/weight-loss-surgery-down-25-as-anti-obesity-drug...
Related News |
25 sources
Current Date
Nov, Fri 1 - 21:57 CET
|